Your browser doesn't support javascript.
Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2.
Vogels, Chantal B F; Breban, Mallery I; Ott, Isabel M; Alpert, Tara; Petrone, Mary E; Watkins, Anne E; Kalinich, Chaney C; Earnest, Rebecca; Rothman, Jessica E; Goes de Jesus, Jaqueline; Morales Claro, Ingra; Magalhães Ferreira, Giulia; Crispim, Myuki A E; Singh, Lavanya; Tegally, Houriiyah; Anyaneji, Ugochukwu J; Hodcroft, Emma B; Mason, Christopher E; Khullar, Gaurav; Metti, Jessica; Dudley, Joel T; MacKay, Matthew J; Nash, Megan; Wang, Jianhui; Liu, Chen; Hui, Pei; Murphy, Steven; Neal, Caleb; Laszlo, Eva; Landry, Marie L; Muyombwe, Anthony; Downing, Randy; Razeq, Jafar; de Oliveira, Tulio; Faria, Nuno R; Sabino, Ester C; Neher, Richard A; Fauver, Joseph R; Grubaugh, Nathan D.
  • Vogels CBF; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
  • Breban MI; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
  • Ott IM; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
  • Alpert T; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
  • Petrone ME; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
  • Watkins AE; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
  • Kalinich CC; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
  • Earnest R; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
  • Rothman JE; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
  • Goes de Jesus J; Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Morales Claro I; Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Magalhães Ferreira G; Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Crispim MAE; Laboratório de Virologia, Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
  • Tegally H; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Anyaneji UJ; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Mason CE; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Khullar G; Tempus Labs, Chicago, Illinois, United States of America.
  • Metti J; Tempus Labs, Chicago, Illinois, United States of America.
  • Dudley JT; Tempus Labs, Chicago, Illinois, United States of America.
  • MacKay MJ; Tempus Labs, Chicago, Illinois, United States of America.
  • Nash M; Tempus Labs, Chicago, Illinois, United States of America.
  • Wang J; Tempus Labs, Chicago, Illinois, United States of America.
  • Liu C; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America.
  • Hui P; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America.
  • Murphy S; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America.
  • Neal C; Murphy Medical Associates, Greenwich, Connecticut, United States of America.
  • Laszlo E; Murphy Medical Associates, Greenwich, Connecticut, United States of America.
  • Landry ML; Murphy Medical Associates, Greenwich, Connecticut, United States of America.
  • Muyombwe A; Departments of Laboratory Medicine and Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
  • Downing R; Connecticut State Department of Public Health, Rocky Hill, Connecticut, United States of America.
  • Razeq J; Connecticut State Department of Public Health, Rocky Hill, Connecticut, United States of America.
  • de Oliveira T; Connecticut State Department of Public Health, Rocky Hill, Connecticut, United States of America.
  • Faria NR; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Sabino EC; Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Neher RA; MRC Centre for Global Infectious Disease Analysis, J-IDEA, Imperial College London, London, United Kingdom.
  • Fauver JR; Department of Zoology, University of Oxford, Oxford, United Kingdom.
  • Grubaugh ND; Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
PLoS Biol ; 19(5): e3001236, 2021 05.
Article in English | MEDLINE | ID: covidwho-1220158
ABSTRACT
With the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants that may increase transmissibility and/or cause escape from immune responses, there is an urgent need for the targeted surveillance of circulating lineages. It was found that the B.1.1.7 (also 501Y.V1) variant, first detected in the United Kingdom, could be serendipitously detected by the Thermo Fisher TaqPath COVID-19 PCR assay because a key deletion in these viruses, spike Δ69-70, would cause a "spike gene target failure" (SGTF) result. However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern (VOC) that lack spike Δ69-70, such as B.1.351 (also 501Y.V2), detected in South Africa, and P.1 (also 501Y.V3), recently detected in Brazil. We identified a deletion in the ORF1a gene (ORF1a Δ3675-3677) in all 3 variants, which has not yet been widely detected in other SARS-CoV-2 lineages. Using ORF1a Δ3675-3677 as the primary target and spike Δ69-70 to differentiate, we designed and validated an open-source PCR assay to detect SARS-CoV-2 VOC. Our assay can be rapidly deployed in laboratories around the world to enhance surveillance for the local emergence and spread of B.1.1.7, B.1.351, and P.1.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: PLoS Biol Journal subject: Biology Year: 2021 Document Type: Article Affiliation country: Journal.pbio.3001236

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: PLoS Biol Journal subject: Biology Year: 2021 Document Type: Article Affiliation country: Journal.pbio.3001236